Share on StockTwits

Qiagen NV (NASDAQ:QGEN) has received an average recommendation of “Hold” from the fourteen ratings firms that are presently covering the stock, AnalystRatingsNetwork.com reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $24.48.

A number of research firms have recently commented on QGEN. Analysts at Barclays reiterated an “equal weight” rating on shares of Qiagen NV in a research note on Tuesday, August 5th. They now have a $24.00 price target on the stock, up previously from $19.00. Separately, analysts at Wedbush raised their price target on shares of Qiagen NV from $19.00 to $20.00 in a research note on Thursday, July 31st. They now have a “neutral” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Qiagen NV from $19.00 to $23.00 in a research note on Thursday, July 31st.

Shares of Qiagen NV (NASDAQ:QGEN) opened at 23.94 on Tuesday. Qiagen NV has a 52 week low of $19.46 and a 52 week high of $25.32. The stock’s 50-day moving average is $24.39 and its 200-day moving average is $22.72. The company has a market cap of $5.570 billion and a P/E ratio of 43.24.

Qiagen NV (NASDAQ:QGEN) last announced its earnings results on Tuesday, July 29th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.01. The company had revenue of $331.20 million for the quarter, compared to the consensus estimate of $330.76 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. Qiagen NV’s revenue was up 4.7% compared to the same quarter last year. Analysts expect that Qiagen NV will post $1.08 EPS for the current fiscal year.

QIAGEN N.V., (NASDAQ:QGEN) is a holding company, which provides sample and assay technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.